Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

814

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

November 12, 2021

Study Completion Date

January 14, 2022

Conditions
COVID
Interventions
DRUG

mavrilimumab

anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])

OTHER

Placebo

matching placebo

Trial Locations (32)

6529

TASK Eden, George

7530

Tiervlei Trial Center, Cape Town

7700

University of Cape Town - Lung Institute, Cape Town

9301

IATROS International, Bloemfontein

15082

Essalud - Hospital de Emergencias Grau, Lima Cercado

15088

Clinica Providencia, San Miguel

15102

Hospital Nacional Cayetano Heredia, San Martín de Porres

19010

Bryn Mawr Hospital, Bryn Mawr

45229

University of Cincinnati, Cincinnati

55407

Allina Health System, Minneapolis

60644

Affinity Health, Chicago

65804

Mercy Clinic Hospitalists, Springfield

70112

Tulane University School of Medicine, New Orleans

77030

University of Texas Health Sciences, Houston

90095

UCLA Medical Center, Los Angeles

92110

SHARP Health Care, San Diego

7550000

Clinica Las Condes, Santiago

8380456

Hospital Clinico Universidad de Chile, Santiago

40170-130

Hospital Cardio Pulmonar, Salvador

30380-472

Hospital Luxemburgo - Associação Mário Penna, Belo Horizonte

59025-050

CPCLIN - Centro de Pesquisas Clínicas, Natal

95900-000

Hospital Bruno Born, Lajeado

18618-686

UPECLIN - Unidade de Pesquisa Clínica, Botucatu

13060-080

IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas

65470-000

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto

66093-904

Hospital Adventista de Belem, Belém

60192-340

IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará, Fortaleza

15090-000

Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José

01323-020

Hospital Alemão Oswaldo Cruz, São Paulo

07011

Hospital Nacional Alberto Sabogal Sologuren, Bellavista

0181

Into Research - Little Company of Mary Medical Center, Pretoria

0299

Limpopo Clinical Research Initiative, Rustenburg

All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, Ltd.

INDUSTRY

lead

Kiniksa Pharmaceuticals International, plc

INDUSTRY

NCT04447469 - Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation | Biotech Hunter | Biotech Hunter